Last checked at 9 Apr 2013 07:00
Port Erin Biopharma Investments Limited ("The Company")
Net Asset Value calculation to 31st March 2013
Jim Mellon, Chairman, commented: -
"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 March 2013 was 11.22 pence per share, including un-invested cash of £287,310. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a considerable increase of 18.1% from the previous valuation of 9.50 pence per share, which included un-invested cash of £101,241. The revenue reserve has increased substantially to just over £1.0 million and represents a return of over 37.2% on investments after listing and operating costs."
| Unaudited to 31 March 2013 £ | |
Fixed Assets |
|
|
| Investments
| 3,434,606 |
Current Assets |
|
|
| Debtors: amounts owing | 5,690 |
| Un-invested cash
| 287,310 |
Current Liabilities |
|
|
| Creditors: amounts due
| (24,000) |
|
| 3,703,606 |
Capital and Reserves |
|
|
| Share Capital | 33 |
| Share Premium | 2,699,011 |
| Capital reserve - realised | 0 |
| Capital reserve - unrealised | 0 |
| Revenue reserve
| 1,004,562 |
| 3,703,606 | |
| ||
Shares in Issue
| 33,000,000 | |
Net Asset Value per share
| 11.22 pence |
--- ENDS ---
Portfolio Details
Investments Schedule at 31st March 2013 | Valuation £ | Portfolio % |
Synergy Pharmaceuticals Inc. | 318,602 | 9.3% |
Gilead Sciences Inc. | 276,677 | 8.1% |
Summit Corporation plc | 254,061 | 7.4% |
Celgene Corporation | 220,975 | 6.4% |
Arrowhead Research | 146,728 | 4.3% |
Pfizer Inc. | 140,322 | 4.1% |
Biogen Idec Inc. | 139,516 | 4.1% |
TrovaGene Inc. | 122,493 | 3.6% |
Nektar Therapeutics | 121,507 | 3.5% |
1,740,882 | 50.7% | |
Aggregate value of remaining holdings below 3% of total portfolio | 1,693,724 | 49.3% |
TOTAL INVESTMENTS | 3,434,606 | 100.0% |
For further information, please contact:
Port Erin Biopharma Investments Ltd | Libertas Capital Corporate Finance Limited | Peterhouse Capital Limited |
The Company | Nomad | Broker |
Denham Eke +44 162 463 9396 | Sandy Jamieson +44 207 569 9650 | Jon Levinson +44 207 562 3350 |